So, based on these data, the authors have concluded that a COX-2 inhibitor, called celecoxib, promotes the proliferation of natural killer T (NKT) cells that enhance specific immune responses and suppress tumor angiogenesis, suggesting a possible role of celecoxib in enhancing immunotherapy effect against LSCC [70]. Here, PTGS2 is linked to neoplasm.